David J. Lefer
About
In The Last Decade
David J. Lefer
283 papers receiving 24.2k citations
Hit Papers
Peers
Comparison fields: 5 of 159
- Physiology 7.4k
- Molecular Biology 7.2k
- Biochemistry 6.9k
- Pathology and Forensic Medicine 5.6k
- Cardiology and Cardiovascular Medicine 5.4k
Countries citing papers authored by David J. Lefer
This map shows the geographic impact of David J. Lefer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Lefer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Lefer more than expected).
Fields of papers citing papers by David J. Lefer
This network shows the impact of papers produced by David J. Lefer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Lefer. The network helps show where David J. Lefer may publish in the future.
Co-authorship network of co-authors of David J. Lefer
This figure shows the co-authorship network connecting the top 25 collaborators of David J. Lefer. A scholar is included among the top collaborators of David J. Lefer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Lefer. David J. Lefer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 4 | |
| 3 | 3 | |
| 4 | 15 | |
| 5 | 40 | |
| 6 | Abstract 19293: Removal of Dietary Trimethylamine N-Oxide (TMAO) Attenuates Cardiac Dysfunction in Pressure Overload Induced Heart Failure | 1 |
| 7 | Abstract 17903: Novel Esterase-Activated Hydrogen Sulfide Donors Attenuate Myocardial Ischemia/Reperfusion Injury | 3 |
| 8 | 8 | |
| 9 | Abstract 16779: A Novel Hydrogen Sulfide Donor Promotes Nitric Oxide Bioavailability in a Phase I Clinical Trial | 1 |
| 10 | 90 | |
| 11 | Abstract 14149: Mitochondrial Targeted DNA Repair Enzyme, Endonuclease III (ENDO III), Attenuates Myocardial Ischemia/Reperfusion Injury | 2 |
| 12 | Abstract 15549: Hydrogen Sulfide Attenuates Cardiac Dysfunction Following Pressure Overload Induced Hypertrophy and Heart Failure Via Augmentation of Angiogenesis | 1 |
| 13 | 259 | |
| 14 | 1 | |
| 15 | 1 | |
| 16 | 95 | |
| 17 | Abstract 3547: Hydrogen Sulfide Therapy Attenuates Left Ventricular Dysfunction and Reduces Mortality in a Murine Model of Heart Failure | 1 |
| 18 | Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver breakdown → | 536 |
| 19 | 97 | |
| 20 | 23 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.